Drugs / [212Pb]VMT-alpha-NET
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06479811 | Aug 2025 → Jan 2029 expected | digestive system neuroendocrine neoplasm, esthesioneuroblastoma, kidney cancer, nasal cavity and paranasal sinus carcinoma +4 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [212Pb]VMT-alpha-NET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06479811 ↗ |
| Modality | Peptide | “VMT-Alpha-NET is a peptide that binds to SSTR” NCT06479811 ↗ |
| Route | Intravenous | “[212Pb]VMT-alpha-NET will be given IV on Day 1 of every cycle for 4 cycles total at escalating doses in Phase I and at MTD during dose expansion.” NCT06479811 ↗ |